Andrea De Luca

Summary

Affiliation: Catholic University
Country: Italy

Publications

  1. doi request reprint Resistance considerations in sequencing of antiretroviral therapy in low-middle income countries with currently available options
    Andrea De Luca
    Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Rome, Italy
    Curr Opin HIV AIDS 5:27-37. 2010
  2. doi request reprint Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1
    Carmela Pinnetti
    Department of Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 15:127-9. 2010
  3. pmc Standardized representation, visualization and searchable repository of antiretroviral treatment-change episodes
    Soo Yon Rhee
    Department of Medicine, Stanford University, Stanford, CA, USA
    AIDS Res Ther 9:13. 2012
  4. pmc Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach
    Dimitrios Paraskevis
    Katholieke Universiteit Leuven, Rega Institute for Medical Research, Minderbroederstraat 10, B 3000 Leuven, Belgium
    Retrovirology 6:49. 2009
  5. pmc Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
    Carlo Torti
    University of Brescia, Italy
    BMC Infect Dis 11:23. 2011
  6. ncbi request reprint Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy
    Andrea De Luca
    Clinical Infectious Diseases, Catholic University, Rome, Italy
    J Infect Dis 193:1219-22. 2006
  7. ncbi request reprint Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Roma, 00168, Italy
    J Infect Dis 196:1645-53. 2007
  8. ncbi request reprint Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    J Infect Dis 187:1934-43. 2003
  9. ncbi request reprint Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Tor Vergata University, Rome, Italy
    Curr Opin Infect Dis 16:573-80. 2003
  10. ncbi request reprint Three-year clinical outcomes of resistance genotyping and expert advice: extended follow-up of the Argenta trial
    Andrea De Luca
    Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Rome, Italy
    Antivir Ther 11:321-7. 2006

Detail Information

Publications89

  1. doi request reprint Resistance considerations in sequencing of antiretroviral therapy in low-middle income countries with currently available options
    Andrea De Luca
    Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Rome, Italy
    Curr Opin HIV AIDS 5:27-37. 2010
    ..Knowledge of the prevalence of transmitted and emerging drug resistance as well as its specific patterns is of help in guiding the selection of appropriate ART types and sequencing strategies...
  2. doi request reprint Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1
    Carmela Pinnetti
    Department of Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 15:127-9. 2010
    ..The analysis of darunavir/ritonavir concentrations in peripheral maternal plasma throughout pregnancy, as well as in umbilical cord blood at delivery, showed low levels of darunavir in the mother and limited transfer across the placenta...
  3. pmc Standardized representation, visualization and searchable repository of antiretroviral treatment-change episodes
    Soo Yon Rhee
    Department of Medicine, Stanford University, Stanford, CA, USA
    AIDS Res Ther 9:13. 2012
    ..abstract:..
  4. pmc Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach
    Dimitrios Paraskevis
    Katholieke Universiteit Leuven, Rega Institute for Medical Research, Minderbroederstraat 10, B 3000 Leuven, Belgium
    Retrovirology 6:49. 2009
    ..However the spatial diffusion of the epidemic from the perspective of the virus has not previously been traced...
  5. pmc Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
    Carlo Torti
    University of Brescia, Italy
    BMC Infect Dis 11:23. 2011
    ..Data regarding CD4+ recovery after switching from protease inhibitor (PI)-based regimens to regimens not containing PI are scarce...
  6. ncbi request reprint Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy
    Andrea De Luca
    Clinical Infectious Diseases, Catholic University, Rome, Italy
    J Infect Dis 193:1219-22. 2006
    ..42 [95% CI, 1.05-1.99]), use of nevirapine (adjusted OR, 1.60 [95% CI, 1.14-2.24]), use of efavirenz (adjusted OR, 1.56 [95% CI, 1.08-2.27]), and use of ritonavir (adjusted OR, 1.35 [95% CI, 1.04-1.75])...
  7. ncbi request reprint Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Roma, 00168, Italy
    J Infect Dis 196:1645-53. 2007
    ..Consensus on the interpretation of mutations in the human immunodeficiency virus (HIV)-1 reverse transcriptase (RT) gene that predict the response to didanosine treatment is needed...
  8. ncbi request reprint Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    J Infect Dis 187:1934-43. 2003
    ..GSSs predicted changes in HIV RNA levels better in adherent patients than in nonadherent individuals. Interpretation may be improved, and knowledge should be used uniformly throughout different expert systems...
  9. ncbi request reprint Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Tor Vergata University, Rome, Italy
    Curr Opin Infect Dis 16:573-80. 2003
    ....
  10. ncbi request reprint Three-year clinical outcomes of resistance genotyping and expert advice: extended follow-up of the Argenta trial
    Andrea De Luca
    Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Rome, Italy
    Antivir Ther 11:321-7. 2006
    ....
  11. doi request reprint Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Lazio Region, Rome, Italy
    AIDS 22:1759-67. 2008
    ..To establish the effectiveness of cidofovir for AIDS-related progressive multifocal leukoencephalopathy (PML) in patients concomitantly receiving combination antiretroviral therapy...
  12. ncbi request reprint Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    Antivir Ther 11:609-18. 2006
    ..A multi-cohort prospective observational comparative study was performed...
  13. doi request reprint Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 16:489-97. 2011
    ..There is not yet consensus on interpretation of genotypic HIV-1 resistance to darunavir (DRV). We validated existing rules and a newly derived score...
  14. ncbi request reprint Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 9:583-93. 2004
    ....
  15. ncbi request reprint Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    Arch Intern Med 162:2125-32. 2002
    ..The effect of chronic coinfection with hepatitis viruses on the response to therapy against human immunodeficiency virus 1 (HIV-1) remains debated...
  16. ncbi request reprint Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 9:743-52. 2004
    ..This work was presented in part at the First European Workshop on HIV Drug Resistance. Luxembourg, 4-6 March 2003 (Abstract 44); and at the 9th European Conference on CIinical AIDS Therapy. Warsaw, 25-28 October 2003 (Abstract F6/7)...
  17. ncbi request reprint Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Policlinoco Universitario Agostino Gemelli, Catholic University of the Sacred Heart, Largo F Vito 1, 00168 Rome, Italy
    J Acquir Immune Defic Syndr 45:411-7. 2007
    ..The extent to which HIV-1 replication capacity (RC) influences the response to therapy remains to be established...
  18. ncbi request reprint Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study
    Simona Di Giambenedetto
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 12:835-9. 2007
    ..We explored the evolution of genotypic drug resistance prevalence in treatment-failing patients from 1999 to 2005 in a clinical cohort...
  19. ncbi request reprint Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation
    Mauro Zaccarelli
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    Antivir Ther 8:51-6. 2003
    ..M184V/I mutation is associated with high-level phenotypic resistance to lamivudine (3TC). The aim of the present analysis was to correlate the time of appearance/disappearance of M184V/I with duration of 3TC treatment...
  20. ncbi request reprint Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA)
    Antonella Cingolani
    Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168 Rome, Italy
    AIDS 16:369-79. 2002
    ....
  21. ncbi request reprint Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation
    Andrea Antinori
    National Institute for Infectious Diseases L Spallanzani IRCCS, Roma, Italy
    Antivir Ther 12:1175-83. 2007
    ..The effect of the HIV reverse transcriptase K65R mutation on virological response to salvage therapy has not been clearly defined...
  22. doi request reprint Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir an
    Simona Di Giambenedetto
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    J Antimicrob Chemother 68:1364-72. 2013
    ..To explore 48 week safety and efficacy of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression on a stable atazanavir/ritonavir-based standard triple regimen...
  23. doi request reprint Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe
    Andrea De Luca
    Catholic University of the Sacred Heart, Rome, Italy
    J Infect Dis 207:1216-20. 2013
    ..5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis...
  24. ncbi request reprint Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals
    Giorgio Antonucci
    National Institute of Infectious Diseases, L Spallanzani, Rome, Italy
    Clin Infect Dis 40:e101-9. 2005
    ..We also aimed to assess whether the response to HAART in these patients varied according to HCV genotype...
  25. ncbi request reprint Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors
    Simona Di Giambenedetto
    Institute of Clinical Infectious DiseasesCatholic University, Rome, Italy
    Scand J Infect Dis 39:813-8. 2007
    ..In patients failing PIs, the interpretation of genotypic resistance to fosamprenavir may change considerably according to the different algorithms and in respect to the effect of pharmacokinetic boosting with ritonavir...
  26. doi request reprint Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1
    Laura Bracciale
    Institute of Clinical of Infectious Disease, Catholic University of Sacred Heart, Rome, Italy
    AIDS Res Hum Retroviruses 25:261-7. 2009
    ..The achievement of virological suppression is a strong predictor of reduced clinical progression...
  27. ncbi request reprint Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics
    Andrea De Luca
    Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Rome, Italy
    J Acquir Immune Defic Syndr 35:359-66. 2004
    ..When these drugs are coadministered, therapeutic drug monitoring should be employed and the IQ can be used to determine target drug levels...
  28. ncbi request reprint Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction?
    Laura Bracciale
    Institute of Clinical Infectious Disease, Catholic University of Sacred Heart, Rome, Italy
    Antivir Ther 14:99-101. 2009
    ....
  29. ncbi request reprint Interpretation systems for genotypic drug resistance of HIV-1
    Andrea De Luca
    Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Rome, Italy
    Scand J Infect Dis Suppl 106:29-34. 2003
    ..Importantly, only 8 systems were intended for clinical use and 5 of these had at least partially undergone clinical validation...
  30. ncbi request reprint Clinical implications of HIV-1 drug resistance in the neurological compartment
    Andrea Antinori
    National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy
    Scand J Infect Dis Suppl 106:41-4. 2003
    ....
  31. ncbi request reprint Characterization of JC virus in cerebrospinal fluid from HIV-1 infected patients with progressive multifocal leukoencephalopathy: insights into viral pathogenesis and disease prognosis
    Angela Marzocchetti
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    J Neurovirol 13:338-46. 2007
    ..To analyze virological and immunological features of AIDS-related progressive multifocal leukoencepalophathy (PML) and their association to disease prognosis...
  32. pmc Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping
    Mattia C F Prosperi
    Infectious Diseases Clinic, Catholic University of Sacred Heart, Rome, Italy
    Retrovirology 7:56. 2010
    ..7% false positive rate cutoff were evaluated using viral DNA and RNA samples, compared against each other and ESTA, using Cohen's kappa, phylogenetic analysis, and area under the receiver operating characteristic (AUROC)...
  33. ncbi request reprint Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy
    Simona Di Giambenedetto
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 14:359-69. 2009
    ..This study aimed to examine the evolution of genotypic drug resistance prevalence in treatment-failing patients in the multicentre, Italian, Antiretroviral Resistance Cohort Analysis (ARCA)...
  34. ncbi request reprint Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens
    Maria Paola Trotta
    Istituto Nazionale per le Malattie Infettive, L Spallanzani IRCCS, Rome, Italy
    AIDS 17:1099-102. 2003
    ..By contrast, younger age, self-report of active drug use, fatigue or vomiting negatively affected adherence. Self-reported sexual dysfunction was significantly associated with non-adherence only in PI-treated individuals...
  35. ncbi request reprint Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group
    Valentina Svicher
    Department of Experimental Medicine, University of Rome, Roma, Italy
    New Microbiol 35:17-25. 2012
    ..The DIVA study is aimed at setting up a standardized genotypic tropism-testing on proviral-DNA for the routine clinical diagnostic-laboratory...
  36. doi request reprint Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice
    Mattia C F Prosperi
    Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    J Med Virol 82:1996-2003. 2010
    ..Despite the likely differences in patient population and adherence, both the low rate of virological failure and the lack of development of LPV/rtv resistance documented in clinical trials are thus confirmed in clinical practice...
  37. pmc A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen
    Mattia C F Prosperi
    Infectious Diseases Clinic, Catholic University of the Sacred Heart, Rome, Italy
    BMC Med Inform Decis Mak 11:40. 2011
    ..However, their relative-hazard for the time to virologic failure has not been thoroughly investigated, and an expert system that is able to predict how long a new cART regimen will remain effective has never been designed...
  38. doi request reprint Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction
    Massimiliano Fabbiani
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    Pharmacol Res 63:249-53. 2011
    ..In conclusion, a potential drug interaction between darunavir and raltegravir was observed, although this did not seem virologically significant. For the distinct metabolic pathways of these drugs, its mechanism remains to be determined...
  39. ncbi request reprint Virologic correlates of adherence to antiretroviral medications and therapeutic failure
    Carlo Federico Perno
    INMI L Spallanzani, Rome, Italy
    J Acquir Immune Defic Syndr 31:S118-22. 2002
    ....
  40. pmc Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy
    Angela Marzocchetti
    Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Largo Gemelli, 8, 00168 Rome, Italy
    J Clin Microbiol 43:4175-7. 2005
    ..5% (95% confidence intervals of 42.1 to 72.9%) in the HAART era; the specificity remained unchanged. Predictors of failure to detect JCV DNA were exposure to HAART at disease onset and higher CD4 counts...
  41. pmc The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies
    Mattia C F Prosperi
    Infectious Diseases Clinic, Catholic University of the Sacred Heart, Rome, Italy
    PLoS ONE 5:e13619. 2010
    ..We introduce the threshold bootstrap clustering (TBC), a new methodology for partitioning molecular sequences, that does not require a phylogenetic tree estimation...
  42. doi request reprint Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice
    Massimiliano Fabbiani
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    J Antimicrob Chemother 64:109-17. 2009
    ....
  43. doi request reprint Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition
    Antonella Cingolani
    Catholic University, Roma, Italy
    Clin Infect Dis 54:853-61. 2012
    ..The impact of human immunodeficiency virus (HIV)-associated tuberculosis on CD4 T-cell count response to combined antiretroviral therapy (cART) is poorly investigated...
  44. doi request reprint Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    J Acquir Immune Defic Syndr 59:236-44. 2012
    ..We investigated the prognostic value of virological and immunological status 6 months after ART initiation with respect to death, loss to follow-up, and treatment switch...
  45. doi request reprint The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy
    Angela Marzocchetti
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    AIDS Res Hum Retroviruses 27:1299-309. 2011
    ..10; p=0.04). Knowledge of the effect of genetic determinants on dyslipidemia and lipodystrophy may prompt the investigation of potential pathogenetic mechanisms and might eventually be used for guiding individualized treatment decisions...
  46. doi request reprint Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study
    Mattia C F Prosperi
    Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    J Antimicrob Chemother 66:1886-96. 2011
    ....
  47. ncbi request reprint Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA)
    Andrea Antinori
    Clinical Department, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS, Roma, Italy
    J Neurovirol 9:47-53. 2003
    ..The use of cidofovir showed a trend towards a reduced risk of death...
  48. doi request reprint Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia
    Nicoletta Ciccarelli
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    Antivir Ther 18:153-60. 2013
    ..The objective of our study was to compare two different central nervous system penetration-effectiveness (CPE) scores for the prediction of cognitive dysfunction in HIV-infected patients...
  49. ncbi request reprint Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University of of Sacred Heart, Rome, Italy
    AIDS 18:1602-4. 2004
    ..Female sex and HCV genotype predicted early virological responses. Results support the early treatment of HCV in co-infected individuals...
  50. doi request reprint Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RAST
    Massimiliano Fabbiani
    From the Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome
    Scand J Infect Dis 46:34-45. 2014
    ....
  51. doi request reprint Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    J Acquir Immune Defic Syndr 59:113-20. 2012
    ..63, P = 0.11; cause-specific aRR 5.27, P = 0.019) than those with haplogroup H. Mitochondrial haplogroups may explain part of the genetic predisposition to lipodystrophy during combination antiretroviral therapy...
  52. ncbi request reprint Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals
    Andrea De Luca
    Istituto di Clinica delle Malattie Infettive, Universita Cattolica del S Cuore, Largo Francesco Vito, I 00168 Rome, Italy
    Neurology 59:342-7. 2002
    ..To investigate in detail factors associated with independent replication of HIV-1 in CNS, and to predict its therapeutic control...
  53. doi request reprint Stochastic modelling of genotypic drug-resistance for human immunodeficiency virus towards long-term combination therapy optimization
    Mattia C F Prosperi
    Department of Computer Science and Automation, University of Roma Tre, Informa Contract Research Organisation, Infectious Disease Clinic, Catholic University of Sacred Heart, Rome, Italy
    Bioinformatics 25:1040-7. 2009
    ..The effect of limited adherence to therapy was also analyzed. Sequential treatment change episodes were also exploited with the aim to evaluate optimal synoptic treatment scenarios...
  54. pmc Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance
    Rita Murri
    Clinica delle Malattie Infettive, Universita Cattolica del S Cuore, 00168 Rome, Italy
    J Gen Intern Med 19:1104-10. 2004
    ..To evaluate the rate of discordance between patients and physicians on adherence to highly active antiretroviral therapy (HAART) and identify factors related to discordance in these two assessments...
  55. ncbi request reprint Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia
    Federica Sora
    Istituto di Ematologia, Universita Cattolica Sacro Cuore, Rome, Italy
    Exp Hematol 30:279-84. 2002
    ..To evaluate the safety, feasibility, and efficacy of allogeneic stem cell transplantation (SCT) for acute myelogenous leukemia (AML) in a young female coinfected by HIV and HCV undergoing highly active antiretroviral therapy (HAART)...
  56. ncbi request reprint Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus
    Stefano Aquaro
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy
    J Med Virol 68:479-88. 2002
    ..In conclusion, the long-term dynamics and the high cumulative virus production that characterize HIV-1 infection of macrophages underscore the peculiar role of these cells as a persistently infected reservoir of HIV...
  57. ncbi request reprint Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group
    Valentina Svicher
    University of Rome Tor Vergata, Department of Experimental Medicine, Roma, Italy
    New Microbiol 33:195-206. 2010
    ..The goal of the OSCAR programme is to evaluate the performances of genotypic HIV-1 tropism testing in clinical practice using the enhanced sensitivity version of Trofile (ESTA) as reference-assay...
  58. doi request reprint A novel methodology for large-scale phylogeny partition
    Mattia C F Prosperi
    Clinic of Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    Nat Commun 2:321. 2011
    ..Our method takes an advantage of a flexible notion of transmission cluster and can become a general framework to analyse other epidemics...
  59. doi request reprint Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients
    Massimiliano Fabbiani
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Largo F Vito 1, 00168 Rome, Italy
    Vaccine 29:2836-9. 2011
    ..These results underscore the usefulness of immunization against influenza in HIV-infected patients, though a boosting dose of vaccine may be required in seriously immunocompromised patients...
  60. doi request reprint Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR
    Cinzia Dello Russo
    Institute of Pharmacology, Catholic University Medical School, Rome, Italy
    Pharmacogenomics 12:567-76. 2011
    ..A fast, sensitive and specific test for HLA-B*57:01 detection has been developed in the present study...
  61. doi request reprint Predictors of Adverse Outcomes in HIV-1-infected Children Receiving Combination Antiretroviral Treatment: Results From a DREAM Cohort in Sub-Saharan Africa
    Maria Cristina Marazzi
    From the Department of Preventive Medicine, LUMSA University Libera Università Maria SS Assunta DREAM Program Department of Biomedicine and Prevention, Tor Vergata University, Via Montpellier, Rome, Italy Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA Azienda Ospedaliedra Universitaria Senese, Siena Università Cattolica Sacro Cuore, Rome, Italy and DREAM Program Mozambique, Maputo, Mozambique
    Pediatr Infect Dis J 33:295-300. 2014
    ..HIV-infected children have less access to combination antiretroviral therapy as compared with adults in resource-limited settings. Growth faltering, loss to follow-up (LTFU) and high mortality are frequently seen...
  62. doi request reprint Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120
    Lucia Lisi
    Institute of Pharmacology, Catholic University Medical School, Rome, Italy
    J Neurochem 120:106-14. 2012
    ..In this experimental paradigm, maraviroc significantly increased microglial activation, thus suggesting that its chronic use can exacerbate neuronal pathology, especially in HIV-experienced patients with higher cerebral IFNγ levels...
  63. ncbi request reprint Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability
    Leonardo Palombi
    Department of Public Health, University Tor Vergata, Catholic University, Rome, Italy
    Clin Infect Dis 48:115-122. 2009
    ..Antiretroviral treatment programs in sub-Saharan Africa have high rates of early mortality and loss to follow-up. Switching to second-line regimens is often delayed because of limited access to laboratory monitoring...
  64. ncbi request reprint Computational models for prediction of response to antiretroviral therapies
    Mattia C F Prosperi
    Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, Emerging Pathogens Institute, University of Florida, Gainesville, FL 32610, USA
    AIDS Rev 14:145-53. 2012
    ..Future perspectives in the field foresee the extension of therapy optimization systems to newly approved antiretroviral drug targets and the prediction of other clinical outcomes, rather than the sole virologic response...
  65. ncbi request reprint An outbreak of HIV-1 subtype G among Italian injecting drug users
    Massimo Ciccozzi
    Epidemiology Unit, Department of Infectious, Parasite and Immune mediated Diseases, Istituto Superiore di Sanita, Rome, Italy
    AIDS 21:1213-5. 2007
    ..All G subtypes but one were found among IDU. The phylogenetic analysis indicated that the outbreak was of monophyletic origin and was caused by HIV-1 strains similar to those from western Africa...
  66. ncbi request reprint Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations
    Carlo Torti
    J Acquir Immune Defic Syndr 35:324-6. 2004
  67. ncbi request reprint Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapy
    Laura Aian Gillini
    J Acquir Immune Defic Syndr 29:546-7. 2002
  68. ncbi request reprint A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads
    Alessandro Cozzi-Lepri
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, University College London, United Kingdom
    J Infect Dis 194:20-8. 2006
    ....
  69. ncbi request reprint [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)]
    Patrizio Pezzotti
    Reparto AIDS MST, Laboratorio di Epidemiologia e Biostatistica, Istituto Superiore di Sanita, Roma
    Epidemiol Prev 27:348-55. 2003
    ..6 (95% CI +34.1; +45.1)per year. This study provides strong evidence that the efficacy of the HAART estimated in the controlled clinical trials has resulted in a real reduction at the population level of morbidity and mortality...
  70. ncbi request reprint Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study
    Cristina Mussini
    Clinic of Infectious and Tropical Diseases, University of Modena and Reggio Emilia, Azienda Policlinico, Modena, Italy
    Clin Infect Dis 38:565-71. 2004
    ..Recurrent cryptococcal infection should be suspected in patients whose serum cryptococcal antigen test results revert back to positive after discontinuation of maintenance therapy...
  71. ncbi request reprint Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure
    Andrea Antinori
    Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, 00149 Rome, Italy
    AIDS Res Hum Retroviruses 18:835-8. 2002
    ..No virological response was observed in six patients harboring a single Y181C/I mutation. On the basis of the present data, sequential use of NNRTIs should be avoided in the management of treatment failure...
  72. ncbi request reprint A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients
    Kristel Van Laethem
    Rega Institute for Medical Research and University Hospitals, Katholieke Universiteit Leuven, Belgium
    Antivir Ther 7:123-9. 2002
    ..The development of a genotypic drug resistance interpretation algorithm, and the evaluation of its power to predict therapy outcome...
  73. ncbi request reprint The influence of hepatitis C virus coinfection on the risk of lipid abnormalities in a cohort of HIV-1-infected patients after initiation of highly active antiretroviral therapy
    Simona Di Giambenedetto
    J Acquir Immune Defic Syndr 36:641-2. 2004
  74. pmc A whole-genome association study of major determinants for host control of HIV-1
    Jacques Fellay
    Center for Population Genomics and Pharmacogenetics, Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27710, USA
    Science 317:944-7. 2007
    ..These findings emphasize the importance of studying human genetic variation as a guide to combating infectious agents...
  75. ncbi request reprint Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis
    Massimo Puoti
    Clinica di Malattie Infettive e Tropical, Universita degli Studi di Brescia, Brescia, Italy
    Antivir Ther 11:567-74. 2006
    ..The impact of lamivudine (3TC) as part of combination antiretroviral therapy (cART) on the risk of liver-related death (LRD) in HIV/hepatitis B virus (HBV)-coinfected patients has not been extensively studied...
  76. doi request reprint Changes in the risk of death after HIV seroconversion compared with mortality in the general population
    Krishnan Bhaskaran
    MRC Clinical Trials Unit, 222 Euston Rd, London NW1 2DA, United Kingdom
    JAMA 300:51-9. 2008
    ..Mortality among human immunodeficiency virus (HIV)-infected individuals has decreased dramatically in countries with good access to treatment and may now be close to mortality in the general uninfected population...
  77. doi request reprint Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women
    Inmaculada Jarrin
    National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
    Am J Epidemiol 168:532-40. 2008
    ..74, 95% CI: 0.56, 0.98). Sex differences in HIV disease progression have become larger and statistically significant in the era of highly active antiretroviral therapy, supporting a stronger impact of health interventions among women...
  78. ncbi request reprint The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes
    David A van de Vijver
    Eijkman Winkler Institute, Department of Virology, University Medical Center Utrecht, G04 614, 3584 CX Utrecht, The Netherlands
    J Acquir Immune Defic Syndr 41:352-60. 2006
    ..This study compared the genetic barrier between subtypes using some 2000 HIV-1 sequences (>600 of non-B subtype) isolated from anti-retroviral-naive patients in Europe...
  79. ncbi request reprint Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop
    Giampiero Carosi
    Department of Infectious Disease, University of Brescia, Brescia, Italy
    AIDS Rev 7:161-7. 2005
    ....
  80. ncbi request reprint Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, School of Medicine, Piazzale Spedali Civili 1, 25123 Brescia, Italy
    J Clin Virol 35:414-9. 2006
    ..To determine the impact of genotypic inhibitory quotient (GIQ) for lopinavir (LPV) in patients failing HAART with limited antiretroviral exposure...
  81. ncbi request reprint Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management
    Annemarie M J Wensing
    Eijkman Winkler Institute, Department of Virology, University Medical Center Utrecht, The Netherlands
    J Infect Dis 192:958-66. 2005
    ..Widespread transmission of drug-resistant variants has the disturbing potential of limiting future therapy options and affecting the efficacy of postexposure prophylaxis...
  82. ncbi request reprint Effect of hepatitis C virus genotype on CD4+ T cell count in a cohort of antiretroviral-naive HIV-1-infected individuals
    Giorgio Antonucci
    J Infect Dis 192:703-4; author reply 704-5. 2005
  83. ncbi request reprint A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regi
    Carlo Torti
    Institute for Infectious and Tropical Diseases, Brescia, Italy
    Clin Infect Dis 40:1828-36. 2005
    ....
  84. ncbi request reprint Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of Antiretroviral-Naive Patients
    Antonella d'Arminio Monforte
    Istituto di Malattie Infettive e Tropicali, Universita di Milano, Milano, Italy
    J Acquir Immune Defic Syndr 38:407-16. 2005
    ....
  85. ncbi request reprint CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l
    Cristina Mussini
    Clinic of Infectious and Tropical Diseases, Azienda Ospedaliero Universitaria Policlinico, University of Modena and Reggio Emilia, Via del Pozzo, 71, 41100 Modena, Italy
    AIDS 19:287-94. 2005
    ..Little is known about CD4 cell count changes in patients with high CD4 cell counts who interrupt antiretroviral therapy, especially in those with a nadir of 250-350 x 10 cells/l...
  86. ncbi request reprint Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system
    Rainer Ziermann
    Bayer HealthCare LLC, Diagnostics Division, 800 Dwight Way, Berkeley, CA 94710, USA
    J Clin Virol 31:S7-15. 2004
    ..Resistance testing is increasingly accepted as a tool in guiding the selection of human immunodeficiency virus type 1 (HIV-1) antiretroviral therapy in HIV-1 infected individuals who fail their current regimen...
  87. ncbi request reprint Triple-nucleoside regimens versus efavirenz
    Andrea De Luca
    N Engl J Med 351:717-9; author reply 717-9. 2004
  88. ncbi request reprint Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis?
    Marco Bongiovanni
    Clinic of Infectious Diseases, San Paolo Hospital, University of Milan, Milan, Italy
    Clin Infect Dis 45:650-3. 2007
    ....
  89. ncbi request reprint Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group
    Cristina Mussini
    Clinic of Infectious and Tropical Diseases, Azienda Ospedaliera Policlinico, University of Modena and Reggio Emilia, Modena, Italy
    Clin Infect Dis 36:645-51. 2003
    ..Patients who present with symptoms after discontinuation of secondary prophylaxis should be evaluated for PCP despite high CD4 count and complete virus suppression...